Gilead Sciences (GILD) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $157.37, +2.49% vs the prior close of $153.54.
- Volume 8.29M shares, 1.4x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
GILD rises 2.5% to $157.37, a 52-week high. Closed at $157.37, +2.49% vs the prior close of $153.54. Day range $156.02–$160.51, opened at $156.39.
GILD daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — GILD rises 2.5% to $157.37, a 52-week high
- Closed at $157.37, +2.49% vs the prior close of $153.54. Day range $156.02–$160.51, opened at $156.39.
- Volume was 8.29M shares, 1.4x its 50-day average of 5.82M.
- Price is +7.5% vs its 50-day average ($146.33) and +14.2% vs its 200-day average ($137.86).
- 52-week range $114.02–$160.51; today's close sits at 93% of that range, 2.0% below the 52-week high.
Oct 14, 2026 — GILD jumps 3.8% to $153.54, a 6-month high
- Closed at $153.54, +3.80% vs the prior close of $147.92. Day range $147.48–$153.76, opened at $148.19.
- Volume was 5.76M shares, 1.0x its 50-day average of 5.90M.
- Price is +5.3% vs its 50-day average ($145.82) and +11.5% vs its 200-day average ($137.70).
- 52-week range $114.02–$157.29; today's close sits at 91% of that range, 2.4% below the 52-week high.
Oct 13, 2026 — GILD dips 1.7% to $147.92
- Closed at $147.92, -1.67% vs the prior close of $150.43. Day range $147.26–$151.16, opened at $151.16.
- Volume was 5.56M shares, 0.9x its 50-day average of 5.94M.
- Price is +1.7% vs its 50-day average ($145.45) and +7.5% vs its 200-day average ($137.55).
- 52-week range $114.02–$157.29; today's close sits at 78% of that range, 6.0% below the 52-week high.
Oct 12, 2026 — GILD dips 0.5% to $150.43
- Closed at $150.43, -0.49% vs the prior close of $151.17. Day range $149.80–$152.26, opened at $151.84.
- Volume was 5.79M shares, 1.0x its 50-day average of 5.96M.
- Price is +3.7% vs its 50-day average ($145.12) and +9.4% vs its 200-day average ($137.44).
- 52-week range $114.02–$157.29; today's close sits at 84% of that range, 4.4% below the 52-week high.
Oct 9, 2026 — GILD rises 2.8% to $151.17, 3 up days in a row
- Closed at $151.17, +2.77% vs the prior close of $147.10. Day range $146.10–$151.44, opened at $147.23.
- Volume was 5.80M shares, 1.0x its 50-day average of 5.98M.
- Price is +4.5% vs its 50-day average ($144.71) and +10.1% vs its 200-day average ($137.32).
- 52-week range $114.02–$157.29; today's close sits at 86% of that range, 3.9% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — GILD ends flat (+0.2%) to $147.10
- Closed at $147.10, +0.17% vs the prior close of $146.85. Day range $144.65–$147.59, opened at $146.73.
- Volume was 4.49M shares, 0.7x its 50-day average of 6.04M.
- Price is +1.9% vs its 50-day average ($144.31) and +7.2% vs its 200-day average ($137.18).
- 52-week range $114.02–$157.29; today's close sits at 76% of that range, 6.5% below the 52-week high.
Oct 7, 2026 — GILD rises 1.8% to $146.85
- Closed at $146.85, +1.82% vs the prior close of $144.23. Day range $144.85–$148.60, opened at $145.28.
- Volume was 5.10M shares, 0.8x its 50-day average of 6.08M.
- Price is +2.0% vs its 50-day average ($144.03) and +7.1% vs its 200-day average ($137.07).
- 52-week range $112.82–$157.29; today's close sits at 77% of that range, 6.6% below the 52-week high.
Oct 6, 2026 — GILD ends flat (-0.3%) to $144.23, 6 down days in a row
- Closed at $144.23, -0.28% vs the prior close of $144.63. Day range $142.60–$146.14, opened at $145.11.
- Volume was 3.72M shares, 0.6x its 50-day average of 6.10M.
- Price is +0.3% vs its 50-day average ($143.78) and +5.3% vs its 200-day average ($136.94).
- 52-week range $112.41–$157.29; today's close sits at 71% of that range, 8.3% below the 52-week high.
- That makes 6 straight losses.
Oct 5, 2026 — GILD ends flat (-0.1%) to $144.63, 5 down days in a row
- Closed at $144.63, -0.08% vs the prior close of $144.74. Day range $142.79–$145.16, opened at $143.21.
- Volume was 6.14M shares, 1.0x its 50-day average of 6.09M.
- Price is +0.8% vs its 50-day average ($143.50) and +5.7% vs its 200-day average ($136.83).
- 52-week range $109.66–$157.29; today's close sits at 73% of that range, 8.0% below the 52-week high.
- That makes 5 straight losses.
Oct 2, 2026 — GILD dips 1.9% to $144.74, 4 down days in a row
- Closed at $144.74, -1.87% vs the prior close of $147.50. Day range $144.00–$148.00, opened at $147.65.
- Volume was 5.04M shares, 0.8x its 50-day average of 6.12M.
- Price is +1.1% vs its 50-day average ($143.20) and +5.9% vs its 200-day average ($136.70).
- 52-week range $108.46–$157.29; today's close sits at 74% of that range, 8.0% below the 52-week high.
- That makes 4 straight losses.
GILD latest news & SEC filings
Every SEC filing by or about GILD in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 2, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- O'Day Daniel Patrick sold 12,000 shares at $147.72 (≈$1.77M) on Oct 1, 2026; now holds 569,683
- O'Day Daniel Patrick sold 3,000 shares at $148.63 (≈$445.88K) on Oct 1, 2026; now holds 566,683
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 23, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Burkhart Erin converted options/RSUs into 2,223 shares on Sep 22, 2026; now holds 2,223
- Burkhart Erin had withheld for taxes 768 shares at $152.67 (≈$117.25K) on Sep 22, 2026; now holds 1,455
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 16, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Dickinson Andrew D sold 3,000 shares at $145.29 (≈$435.87K) on Sep 15, 2026; now holds 164,096
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 16, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Mercier Johanna sold 1,600 shares at $143.69 (≈$229.91K) on Sep 15, 2026; now holds 118,084
- Mercier Johanna sold 800 shares at $144.46 (≈$115.57K) on Sep 15, 2026; now holds 117,284
- Mercier Johanna sold 600 shares at $145.29 (≈$87.17K) on Sep 15, 2026; now holds 116,684
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 15, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 15, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 26, 2026 · N-PX — Annual proxy voting record
Annual proxy voting record
Aug 7, 2026 · SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · S-3ASR — S-3ASR filing
S-3ASR filing
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 6, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $7.80B (prior year $7.08B) (+10.2% vs Jun 30, 2025)
- Net income: -$10.50B (prior year $1.96B) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$8.45 (prior year $1.56) (loss widened vs Jun 30, 2025)
Aug 4, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 3, 2026 · 13F-HR — Quarterly holdings report filed by an institutional investment manager
Quarterly holdings report filed by an institutional investment manager
Things to know before you trade GILD
- Last results release: Aug 4, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 10, 2026, Oct 30, 2025. Based on that rhythm, the next report is likely around Nov 3, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.22% (largest 3.8%).
- Liquidity: about 5.97M shares (≈$940.23M) trade per day on average.
- 52-week position: $157.37 vs a range of $114.02–$160.51 (93% of the range).
- Dividends: last ex-dividend date Sep 15, 2026 ($0.82/share); 4 payments in the past 12 months.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Andrew D Dickinson sold 3,000 shares on Sep 15, 2026.
- Latest filings: 10-Q Aug 6, 2026; 8-K Aug 4, 2026; 8-K May 20, 2026.
- Share count: 1.24B shares outstanding (Jul 31, 2026), -0.1% vs a year earlier.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
GILD market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 156.39 | 160.51 | 156.02 | 157.37 | 8.29M |
| Oct 14, 2026 | 148.19 | 153.76 | 147.48 | 153.54 | 5.76M |
| Oct 13, 2026 | 151.16 | 151.16 | 147.26 | 147.92 | 5.56M |
| Oct 12, 2026 | 151.84 | 152.26 | 149.80 | 150.43 | 5.79M |
| Oct 9, 2026 | 147.23 | 151.44 | 146.10 | 151.17 | 5.80M |
| Oct 8, 2026 | 146.73 | 147.59 | 144.65 | 147.10 | 4.49M |
| Oct 7, 2026 | 145.28 | 148.60 | 144.85 | 146.85 | 5.10M |
| Oct 6, 2026 | 145.11 | 146.14 | 142.60 | 144.23 | 3.72M |
| Oct 5, 2026 | 143.21 | 145.16 | 142.79 | 144.63 | 6.14M |
| Oct 2, 2026 | 147.65 | 148.00 | 144.00 | 144.74 | 5.04M |
| Oct 1, 2026 | 149.44 | 149.44 | 147.19 | 147.50 | 4.44M |
| Sep 30, 2026 | 150.88 | 151.28 | 148.98 | 149.05 | 5.36M |
| Sep 29, 2026 | 150.18 | 152.63 | 148.79 | 151.28 | 5.32M |
| Sep 28, 2026 | 149.80 | 152.74 | 149.41 | 152.21 | 5.08M |
| Sep 25, 2026 | 150.05 | 151.00 | 148.02 | 150.93 | 5.28M |
| Sep 24, 2026 | 151.10 | 152.98 | 149.59 | 149.69 | 5.07M |
| Sep 23, 2026 | 153.60 | 154.20 | 150.06 | 151.37 | 6.19M |
| Sep 22, 2026 | 150.65 | 153.28 | 148.65 | 152.67 | 5.08M |
| Sep 21, 2026 | 150.11 | 152.10 | 148.22 | 150.56 | 5.57M |
| Sep 18, 2026 | 150.56 | 153.23 | 149.57 | 150.11 | 16.41M |
About Gilead Sciences
Gilead Sciences (GILD) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in FOSTER CITY, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 882095.
GILD board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Jacqueline K Barton | Director | May 4, 2026 |
| Jeffrey Bluestone | Director | Aug 21, 2026 |
| Sandra Horning | Director | May 4, 2026 |
| Kelly A. Kramer | Director | May 4, 2026 |
| Ted W Love | Director | May 4, 2026 |
| Harish Manwani | Director | May 4, 2026 |
| Daniel Patrick O'Day | Chairman & CEO | Sep 11, 2026 |
| Javier Rodriguez | Director | May 4, 2026 |
| Anthony Welters | Director | Aug 27, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Dietmar Berger | Chief Medical Officer | Sep 11, 2026 |
| Erin Burkhart | SVP, Controllership | Sep 23, 2026 |
| Wettan Keeley M Cain | EVP Gen Counsel, Legal & Comp | Sep 11, 2026 |
| Andrew D Dickinson | Chief Financial Officer | Sep 16, 2026 |
| Johanna Mercier | Chief Comm & Corp Aff Officer | Sep 16, 2026 |
| Daniel Patrick O'Day | Chairman & CEO | Sep 11, 2026 |
| Deborah H Telman | EVP, Corporate Affairs & GC | Nov 13, 2025 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 15, 2026 | Andrew D Dickinson | Sale | 3,000 | $145.29 |
| Sep 15, 2026 | Johanna Mercier | Sale | 1,600 | $143.69 |
| Sep 15, 2026 | Johanna Mercier | Sale | 800 | $144.46 |
| Sep 15, 2026 | Johanna Mercier | Sale | 600 | $145.29 |
| Sep 1, 2026 | Daniel Patrick O'Day | Sale | 1,600 | $147.51 |
| Sep 1, 2026 | Daniel Patrick O'Day | Sale | 7,992 | $148.36 |
| Sep 1, 2026 | Daniel Patrick O'Day | Sale | 5,408 | $149.38 |
| Aug 26, 2026 | Anthony Welters | Sale | 4,600 | $148.82 |
| Aug 26, 2026 | Anthony Welters | Sale | 6,880 | $148.82 |
| Aug 26, 2026 | Anthony Welters | Sale | 3,402 | $148.24 |
| Aug 26, 2026 | Anthony Welters | Sale | 3,118 | $148.31 |
| Aug 20, 2026 | Jeffrey Bluestone | Sale | 1,658 | $145.73 |
| Aug 20, 2026 | Jeffrey Bluestone | Sale | 1,816 | $144.92 |
| Aug 20, 2026 | Jeffrey Bluestone | Sale | 1,165 | $143.75 |
| Aug 20, 2026 | Jeffrey Bluestone | Sale | 335 | $146.26 |
GILD financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $29.44B | $8.51B | 6.78 | $10.02B |
| Dec 31, 2024 | $28.75B | $480.00M | 0.38 | $10.83B |
| Dec 31, 2023 | $27.12B | $5.67B | 4.50 | $8.01B |
| Dec 31, 2022 | $27.28B | $4.59B | 3.64 | $9.07B |
| Dec 31, 2021 | $27.30B | $6.22B | 4.93 | $11.38B |
Latest balance sheet: total assets $49.36B, total liabilities $—, cash $5.41B (as of Jun 30, 2026).
GILD earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 4, 2026 | 8-K Item 2.02 (results) | $135.25 |
| May 7, 2026 | 8-K Item 2.02 (results) | $134.06 |
| Feb 10, 2026 | 8-K Item 2.02 (results) | $147.23 |
| Oct 30, 2025 | 8-K Item 2.02 (results) | $118.44 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $110.28 |
| Apr 24, 2025 | 8-K Item 2.02 (results) | $106.15 |
| Feb 11, 2025 | 8-K Item 2.02 (results) | $96.14 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $91.69 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| Apr 25, 2024 | 8-K Item 2.02 (results) | — |
| Feb 6, 2024 | 8-K Item 2.02 (results) | — |
| Nov 7, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Twist Bioscience (TWST)Argenx Se (ARGX)Biogen (BIIB)Halozyme Therapeutics (HALO)Revolution Medicines (RVMD)Recursion Pharmaceuticals (RXRX)ImmunityBio (IBRX)Repligen (RGEN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on GILD
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.